pentostatin + rituximab

Pentostatin + rituximab is a **combination therapy** consisting of two agents: - **Pentostatin** is a purine analog antimetabolite that selectively inhibits adenosine deaminase, leading to cytotoxic accumulation of metabolites in lymphocytes, predominantly affecting DNA synthesis in S-phase cells. - **Rituximab** is a monoclonal antibody targeting CD20 on B lymphocytes, mediating cell lysis via complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. This combination is used chiefly for treating B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma (NHL), particularly in both relapsed and previously untreated patients. The regimen leverages the modest toxicity and outpatient feasibility of both agents, aiming to improve response rates in indolent and intermediate-grade B-cell lymphoid cancers[5][7].